
Herbert Loong/immunooncologyindia.com
Apr 7, 2025, 11:42
Herbert Loong: The safety and feasibility of outpatient administration of tarlatamab as part of the DeLLphi300 study
Herbert Loong, Chair-Elect of the International Affairs Committee at American Society of Clinical Oncology (ASCO), shared an article by A.C. Chiang, et al. on LinkedIn:
“Happy to share our recent ESMO Open paper on the safety and feasibility of outpatient administration of tarlatamab as part of the DeLLphi300 study providing evidence that support less intensive monitoring at initiation of therapy.
Luis Paz-Ares, Noemi Reguart, Shirish Gadgeel and others.”
Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy.
Authors: A.C. Chiang, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 7, 2025, 10:47
Apr 7, 2025, 10:38
Apr 7, 2025, 10:37
Apr 7, 2025, 10:22